Foxx Development Holdings Inc. (NASDAQ:FOXX – Get Free Report) was the recipient of a significant decline in short interest in July. As of July 15th, there was short interest totaling 33,622 shares, a decline of 47.5% from the June 30th total of 64,095 shares. Based on an average daily trading volume, of 25,613 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.7% of the shares of the stock are short sold.
Foxx Development Price Performance
Shares of FOXX stock traded down $0.23 during midday trading on Wednesday, reaching $2.35. 5,206 shares of the company traded hands, compared to its average volume of 725,491. The firm’s 50 day simple moving average is $3.22 and its two-hundred day simple moving average is $4.22. The firm has a market cap of $16.58 million, a PE ratio of -0.34 and a beta of -0.39. Foxx Development has a 1-year low of $1.71 and a 1-year high of $8.88.
Foxx Development (NASDAQ:FOXX – Get Free Report) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($5.19) earnings per share for the quarter. The company had revenue of $8.67 million during the quarter.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on FOXX
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Foxx Development stock. Citadel Advisors LLC acquired a new position in shares of Foxx Development Holdings Inc. (NASDAQ:FOXX – Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 12,025 shares of the company’s stock, valued at approximately $57,000. Citadel Advisors LLC owned about 0.18% of Foxx Development at the end of the most recent reporting period. 60.44% of the stock is currently owned by institutional investors.
Foxx Development Company Profile
Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.
Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.
Featured Stories
- Five stocks we like better than Foxx Development
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Foxx Development Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foxx Development and related companies with MarketBeat.com's FREE daily email newsletter.
